Top

Published in:

Open Access 01-12-2008 | Research

Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer

Authors: Paul P Anglim, Janice S Galler, Michael N Koss, Jeffrey A Hagen, Sally Turla, Mihaela Campan, Daniel J Weisenberger, Peter W Laird, Kimberly D Siegmund, Ite A Laird-Offringa

Published in: Molecular Cancer | Issue 1/2008

Abstract

Background

Lung cancer is the leading cause of cancer death in men and women in the United States and Western Europe. Over 160,000 Americans die of this disease every year. The five-year survival rate is 15% – significantly lower than that of other major cancers. Early detection is a key factor in increasing lung cancer patient survival. DNA hypermethylation is recognized as an important mechanism for tumor suppressor gene inactivation in cancer and could yield powerful biomarkers for early detection of lung cancer. Here we focused on developing DNA methylation markers for squamous cell carcinoma of the lung. Using the sensitive, high-throughput DNA methylation analysis technique MethyLight, we examined the methylation profile of 42 loci in a collection of 45 squamous cell lung cancer samples and adjacent non-tumor lung tissues from the same patients.

Results

We identified 22 loci showing significantly higher DNA methylation levels in tumor tissue than adjacent non-tumor lung. Of these, eight showed highly significant hypermethylation in tumor tissue (p < 0.0001): GDNF, MTHFR, OPCML, TNFRSF25, TCF21, PAX8, PTPRN2 and PITX2. Used in combination on our specimen collection, this eight-locus panel showed 95.6% sensitivity and specificity.

Conclusion

We have identified 22 DNA methylation markers for squamous cell lung cancer, several of which have not previously been reported to be methylated in any type of human cancer. The top eight markers show great promise as a sensitive and specific DNA methylation marker panel for squamous cell lung cancer.

Available only for authorised users

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57 (1): 43-66.CrossRefPubMed

Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, Naruke T, Suemasu K, Moriyama N: Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology. 1996, 201 (3): 798-802.CrossRefPubMed

Gavelli G, Giampalma E: Sensitivity and specificity of chest X-ray screening for lung cancer: review article. Cancer. 2000, 89 (11 Suppl): 2453-2456. 10.1002/1097-0142(20001201)89:11+<2453::AID-CNCR21>3.0.CO;2-MCrossRefPubMed

Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS: Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006, 355 (17): 1763-1771. 10.1056/NEJMoa060476CrossRefPubMed

Crestanello JA, Allen MS, Jett JR, Cassivi SD, Nichols FC, Swensen SJ, Deschamps C, Pairolero PC: Thoracic surgical operations in patients enrolled in a computed tomographic screening trial. J Thorac Cardiovasc Surg. 2004, 128 (2): 254-259. 10.1016/j.jtcvs.2004.02.017CrossRefPubMed

Diederich S, Wormanns D: Impact of low-dose CT on lung cancer screening. Lung Cancer. 2004, 45 (Suppl 2): S13-19. 10.1016/j.lungcan.2004.07.997CrossRefPubMed

McWilliams A, MacAulay C, Gazdar AF, Lam S: Innovative molecular and imaging approaches for the detection of lung cancer and its precursor lesions. Oncogene. 2002, 21 (45): 6949-6959. 10.1038/sj.onc.1205831CrossRefPubMed

Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB: Computed tomography screening and lung cancer outcomes. Jama. 2007, 297 (9): 953-961. 10.1001/jama.297.9.953CrossRefPubMed

Haussinger K, Becker H, Stanzel F, Kreuzer A, Schmidt B, Strausz J, Cavaliere S, Herth F, Kohlhaufl M, Muller KM: Autofluorescence bronchoscopy with white light bronchoscopy compared with white light bronchoscopy alone for the detection of precancerous lesions: a European randomised controlled multicentre trial. Thorax. 2005, 60 (6): 496-503. 10.1136/thx.2005.041475PubMedCentralCrossRefPubMed

10.

Feller-Kopman D, Lunn W, Ernst A: Autofluorescence bronchoscopy and endobronchial ultrasound: a practical review. Ann Thorac Surg. 2005, 80 (6): 2395-2401. 10.1016/j.athoracsur.2005.04.084CrossRefPubMed

11.

Bach PB, Kelley MJ, Tate RC, McCrory DC: Screening for lung cancer: a review of the current literature. Chest. 2003, 123 (1 Suppl): 72S-82S. 10.1378/chest.123.1_suppl.72SCrossRefPubMed

12.

Li R, Todd NW, Qiu Q, Fan T, Zhao RY, Rodgers WH, Fang HB, Katz RL, Stass SA, Jiang F: Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer. Clin Cancer Res. 2007, 13 (2): 482-487. 10.1158/1078-0432.CCR-06-1593CrossRefPubMed

13.

Laird PW, Jaenisch R: The role of DNA methylation in cancer genetic and epigenetics. Annu Rev Genet. 1996, 30: 441-464. 10.1146/annurev.genet.30.1.441CrossRefPubMed

14.

Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000, 28 (8): E32- 10.1093/nar/28.8.e32PubMedCentralCrossRefPubMed

15.

Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 2004, 4 (9): 707-717. 10.1038/nrc1432CrossRefPubMed

16.

de Fraipont F, Moro-Sibilot D, Michelland S, Brambilla E, Brambilla C, Favrot MC: Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer?. Lung Cancer. 2005, 50 (2): 199-209. 10.1016/j.lungcan.2005.05.019CrossRefPubMed

17.

Field JK, Liloglou T, Warrak S, Burger M, Becker E, Berlin K, Nimmrich I, Maier S: Methylation discriminators in NSCLC identified by a microarray based approach. Int J Oncol. 2005, 27 (1): 105-111.PubMed

18.

Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K: DNA methylation profiles of lung tumors. Mol Cancer Ther. 2001, 1 (1): 61-67.PubMed

19.

Ehrich M, Field JK, Liloglou T, Xinarianos G, Oeth P, Nelson MR, Cantor CR, Boom van den D: Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res. 2006, 66 (22): 10911-10918. 10.1158/0008-5472.CAN-06-0400CrossRefPubMed

20.

Vischioni B, Oudejans JJ, Vos W, Rodriguez JA, Giaccone G: Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther. 2006, 5 (11): 2905-2913. 10.1158/1535-7163.MCT-06-0301CrossRefPubMed

21.

Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK, Lam WK, Chiu SW, Girard L, Minna JD: Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res. 2006, 12 (5): 1647-1653. 10.1158/1078-0432.CCR-05-1981CrossRefPubMed

22.

Zhou W, Heist RS, Liu G, Neuberg DS, Asomaning K, Su L, Wain JC, Lynch TJ, Giovannucci E, Christiani DC: Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2006, 15 (11): 2239-2245. 10.1158/1055-9965.EPI-06-0023CrossRefPubMed

23.

Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, Macdonald J, Thomas D, Moskaluk C, Wang Y: Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006, 66 (15): 7466-7472. 10.1158/0008-5472.CAN-06-1191CrossRefPubMed

24.

Tsou JA, Galler JS, Siegmund KD, Laird PW, Turla S, Cozen W, Hagen JA, Koss MN, Laird-Offringa IA: Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer. 2007, 6: 70- 10.1186/1476-4598-6-70PubMedCentralCrossRefPubMed

25.

Janssen-Heijnen ML, Coebergh JW: Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer. 2001, 31 (2–3): 123-137. 10.1016/S0169-5002(00)00197-5CrossRefPubMed

26.

Dammann R, Strunnikova M, Schagdarsurengin U, Rastetter M, Papritz M, Hattenhorst UE, Hofmann HS, Silber RE, Burdach S, Hansen G: CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer. 2005, 41 (8): 1223-1236. 10.1016/j.ejca.2005.02.020CrossRefPubMed

27.

Kim YT, Lee SH, Sung SW, Kim JH: Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?. Ann Thorac Surg. 2005, 79 (4): 1180-1188. discussion 1180–1188, 10.1016/j.athoracsur.2004.09.060CrossRefPubMed

28.

Safar AM, Spencer H, Su X, Coffey M, Cooney CA, Ratnasinghe LD, Hutchins LF, Fan CY: Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res. 2005, 11 (12): 4400-4405. 10.1158/1078-0432.CCR-04-2378CrossRefPubMed

29.

Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 2005, 57: 289-300.

30.

Virmani AK, Tsou JA, Siegmund KD, Shen LY, Long TI, Laird PW, Gazdar AF, Laird-Offringa IA: Hierarchical clustering of lung cancer cell lines using DNA methylation markers. Cancer Epidemiol Biomarkers Prev. 2002, 11 (3): 291-297.PubMed

31.

Nakas CT, Alonzo TA: ROC graphs for assessing the ability of a diagnostic marker to detect three disease classes with an umbrella ordering. Biometrics. 2007, 63 (2): 603-609. 10.1111/j.1541-0420.2006.00715.xCrossRefPubMed

32.

Smith LT, Lin M, Brena RM, Lang JC, Schuller DE, Otterson GA, Morrison CD, Smiraglia DJ, Plass C: Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci USA. 2006, 103 (4): 982-987. 10.1073/pnas.0510171102PubMedCentralCrossRefPubMed

33.

Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001, 61 (1): 249-255.PubMed

34.

Brabender J, Usadel H, Metzger R, Schneider PM, Park J, Salonga D, Tsao-Wei DD, Groshen S, Lord RV, Takebe N: Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res. 2003, 9 (1): 223-227.PubMed

35.

Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR, Wu X: Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006, 12 (24): 7329-7338. 10.1158/1078-0432.CCR-06-0894CrossRefPubMed

36.

Harden SV, Tokumaru Y, Westra WH, Goodman S, Ahrendt SA, Yang SC, Sidransky D: Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res. 2003, 9 (4): 1370-1375.PubMed

37.

Rauch T, Li H, Wu X, Pfeifer GP: MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res. 2006, 66 (16): 7939-7947. 10.1158/0008-5472.CAN-06-1888CrossRefPubMed

38.

Marsit CJ, Houseman EA, Christensen BC, Eddy K, Bueno R, Sugarbaker DJ, Nelson HH, Karagas MR, Kelsey KT: Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res. 2006, 66 (21): 10621-10629. 10.1158/0008-5472.CAN-06-1687CrossRefPubMed

39.

Dai Z, Lakshmanan RR, Zhu WG, Smiraglia DJ, Rush LJ, Fruhwald MC, Brena RM, Li B, Wright FA, Ross P: Global methylation profiling of lung cancer identifies novel methylated genes. Neoplasia. 2001, 3 (4): 314-323. 10.1038/sj.neo.7900162PubMedCentralCrossRefPubMed

40.

Liu Y, Lan Q, Siegfried JM, Luketich JD, Keohavong P: Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia. 2006, 8 (1): 46-51. 10.1593/neo.05586PubMedCentralCrossRefPubMed

41.

Furonaka O, Takeshima Y, Awaya H, Kushitani K, Kohno N, Inai K: Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma. Pathol Int. 2005, 55 (6): 303-309. 10.1111/j.1440-1827.2005.01830.xCrossRefPubMed

42.

Guo M, House MG, Hooker C, Han Y, Heath E, Gabrielson E, Yang SC, Baylin SB, Herman JG, Brock MV: Promoter hypermethylation of resected bronchial margins: a field defect of changes?. Clin Cancer Res. 2004, 10 (15): 5131-5136. 10.1158/1078-0432.CCR-03-0763CrossRefPubMed

43.

Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RC: ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene. 2003, 22 (19): 2897-2909. 10.1038/sj.onc.1206380CrossRefPubMed

44.

Suzuki M, Shigematsu H, Shames DS, Sunaga N, Takahashi T, Shivapurkar N, Iizasa T, Frenkel EP, Minna JD, Fujisawa T: DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer. 2005, 93 (9): 1029-1037. 10.1038/sj.bjc.6602837PubMedCentralCrossRefPubMed

45.

Hanabata T, Tsukuda K, Toyooka S, Yano M, Aoe M, Nagahiro I, Sano Y, Date H, Shimizu N: DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers. Oncol Rep. 2004, 12 (1): 177-180.PubMed

46.

Maneckjee R, Minna JD: Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ. 1994, 5 (10): 1033-1040.PubMed

47.

Friedrich MG, Weisenberger DJ, Cheng JC, Chandrasoma S, Siegmund KD, Gonzalgo ML, Toma MI, Huland H, Yoo C, Tsai YC: Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res. 2004, 10 (22): 7457-7465. 10.1158/1078-0432.CCR-04-0930CrossRefPubMed

48.

Blum M, Steinbeisser H, Campione M, Schweickert A: Vertebrate left-right asymmetry: old studies and new insights. Cell Mol Biol (Noisy-le-grand). 1999, 45 (5): 505-516.

49.

Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP: Methylation profiling in acute myeloid leukemia. Blood. 2001, 97 (9): 2823-2829. 10.1182/blood.V97.9.2823CrossRefPubMed

50.

Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nahrig J: DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – Technical and clinical validation in a multi-centre setting in collaboration with the European organisation for research and treatment of cancer (EORTC) pathobiology group. Eur J Cancer. 2007, 43 (11): 1679-1686. 10.1016/j.ejca.2007.04.025CrossRefPubMed

51.

Hampton T: New Markers may help predict prostate cancer relapse risk. Journal of the American Medical Association. 2006, 295 (19): 2234-2238. 10.1001/jama.295.19.2234CrossRefPubMed

52.

Li Q, Borovitskaya AE, DeSilva MG, Wasserfall C, Maclaren NK, Notkins AL, Lan MS: Autoantigens in insulin-dependent diabetes mellitus: molecular cloning and characterization of human IA-2 beta. Proc Assoc Am Physicians. 1997, 109 (4): 429-439.PubMed

53.

Garnis C, Davies JJ, Buys TP, Tsao MS, MacAulay C, Lam S, Lam WL: Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression. Oncogene. 2005, 24 (30): 4806-4812. 10.1038/sj.onc.1208643CrossRefPubMed

54.

Fromont-Hankard G, Philippe-Chomette P, Delezoide AL, Nessmann C, Aigrain Y, Peuchmaur M: Glial cell-derived neurotrophic factor expression in normal human lung and congenital cystic adenomatoid malformation. Arch Pathol Lab Med. 2002, 126 (4): 432-436.PubMed

55.

Funahashi H, Okada Y, Sawai H, Takahashi H, Matsuo Y, Takeyama H, Manabe T: The role of glial cell line-derived neurotrophic factor (GDNF) and integrins for invasion and metastasis in human pancreatic cancer cells. J Surg Oncol. 2005, 91 (1): 77-83. 10.1002/jso.20277CrossRefPubMed

56.

Grimm L, Holinski-Feder E, Teodoridis J, Scheffer B, Schindelhauer D, Meitinger T, Ueffing M: Analysis of the human GDNF gene reveals an inducible promoter, three exons, a triplet repeat within the 3'-UTR and alternative splice products. Hum Mol Genet. 1998, 7 (12): 1873-1886. 10.1093/hmg/7.12.1873CrossRefPubMed

57.

Mountain CF: The international system for staging lung cancer. Semin Surg Oncol. 2000, 18 (2): 106-115. 10.1002/(SICI)1098-2388(200003)18:2<106::AID-SSU4>3.0.CO;2-PCrossRefPubMed

58.

Laird PW, Zijderveld A, Linders K, Rudnicki MA, Jaenisch R, Berns A: Simplified mammalian DNA isolation procedure. Nucleic Acids Res. 1991, 19 (15): 4293- 10.1093/nar/19.15.4293PubMedCentralCrossRefPubMed

59.

Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006, 38 (7): 787-793. 10.1038/ng1834CrossRefPubMed

60.

Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird PW: CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. 1999, 59 (10): 2302-2306.PubMed

61.

Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, Ehrlich M, Laird PW: Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 2005, 33 (21): 6823-6836. 10.1093/nar/gki987PubMedCentralCrossRefPubMed

62.

Ihaka R, Gentleman R: R: a language for data analysis and graphics. J Comput Graph Statist. 1996, 5: 299-314. 10.2307/1390807. 10.2307/1390807

63.

GeneCards. http://www.genecards.org

Title: Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer
Authors: Paul P Anglim
Janice S Galler
Michael N Koss
Jeffrey A Hagen
Sally Turla
Mihaela Campan
Daniel J Weisenberger
Peter W Laird
Kimberly D Siegmund
Ite A Laird-Offringa
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2008
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-7-62

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2008

Gene expression time-series analysis of Camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines

Down-regulation of transforming growth factor-β type II receptor (TGF-βRII) protein and mRNA expression in cervical cancer

Identification and transcript analysis of a novel wallaby (Macropus eugenii) basal-like breast cancer cell line

Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity

Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer